Compare DELL & JNJ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DELL | JNJ |
|---|---|---|
| Founded | 1984 | 1886 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 191.7B | 542.4B |
| IPO Year | 2013 | 2003 |
| Metric | DELL | JNJ |
|---|---|---|
| Price | $424.59 | $228.38 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 17 | 20 |
| Target Price | $181.63 | ★ $238.20 |
| AVG Volume (30 Days) | ★ 10.0M | 6.4M |
| Earning Date | 05-28-2026 | 04-14-2026 |
| Dividend Yield | 1.23% | ★ 2.36% |
| EPS Growth | 36.05 | ★ 90.50 |
| EPS | ★ 5.24 | 2.14 |
| Revenue | ★ $113,538,000,000.00 | N/A |
| Revenue This Year | $26.19 | $6.63 |
| Revenue Next Year | $8.60 | $7.43 |
| P/E Ratio | ★ $79.67 | $108.94 |
| Revenue Growth | ★ 18.80 | N/A |
| 52 Week Low | $110.22 | $149.04 |
| 52 Week High | $469.47 | $251.71 |
| Indicator | DELL | JNJ |
|---|---|---|
| Relative Strength Index (RSI) | 68.54 | 45.46 |
| Support Level | $122.88 | $221.66 |
| Resistance Level | $469.47 | $244.80 |
| Average True Range (ATR) | 29.76 | 4.53 |
| MACD | -2.68 | 0.12 |
| Stochastic Oscillator | 62.44 | 39.50 |
Dell Technologies is a broad information technology vendor, primarily supplying hardware to enterprises. It focuses on premium and commercial personal computers, as well as enterprise on-premises data center hardware. It holds top-three shares in its core markets of personal computers, peripheral displays, mainstream servers, and external storage. Dell has a robust ecosystem of component and assembly partners and also relies heavily on channel partners to fulfill its sales.
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.